Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 29;15(10):e0240393. doi: 10.1371/journal.pone.0240393

The first wave of COVID-19 in Israel—Initial analysis of publicly available data

Mark Last 1,*
Editor: Stefan Cristian Gherghina2
PMCID: PMC7595440  PMID: 33119605

Abstract

The first case of COVID-19 was confirmed in Israel on February 21, 2020. Within approximately 30 days, the total number of confirmed cases climbed up to 1, 000, accompanied by a doubling period of less than 3 days. About one week later, after this number exceeded 4, 000 cases, and following some extreme lockdown measures taken by the Israeli government, the daily infection rate started a sharp decrease from the peak value of 1, 131 down to slightly more than 100 new confirmed cases on April 30. Motivated by this encouraging data, similar to the trends observed in many other countries, along with the growing economic pressures, the Israeli government has quickly lifted most of its emergency regulations. Throughout May, the daily number of new cases stayed at a very low level of 20–40 until at the end of May it started a steady increase, exceeding 1, 000 by the end of June and 2, 000 on July 22. As suggested by some experts and popular media, this disturbing trend may be even a part of a “second wave”. This article attempts to analyze the data available on Israel at the end of July 2020, compared to three European countries (Greece, Italy, and Sweden), in order to understand the local dynamics of COVID-19, assess the effect of the implemented intervention measures, and discuss some plausible scenarios for the foreseeable future.

Introduction

The first case of COVID-19 was confirmed in Israel on February 21, 2020. On March 9, a two-week self-isolation was imposed on all people coming from abroad and on March 12, schools and universities were closed by the government order, partially switching to distant teaching. Then, on March 19, when the number of daily confirmed cases exceeded 100, all non-essential businesses were ordered to close, the employees were required to increase social distancing of their workers and, if possible, allow them to work from home, whereas people’s movement outside their homes was restricted significantly. Still, by March 23, the number of confirmed cases climbed up to 1, 000, accompanied by a doubling period of less than 3 days. A continuous decrease in the growth rate has started only around March 29, after the total number of confirmed cases exceeded 4, 000.

With the peak unemployment rate of 24%, mostly due to people placed on unpaid leave as a result of the pandemic, the Israeli government decided to partially lift the lockdown, which has been maintained throughout the Passover holiday (April 7-16). The “exit strategy” steps under consideration included increasing the allowed percentage of workers at workplaces, opening some shops, partially resuming public transportation, gradually getting children back to school, and selectively releasing people from the movement restrictions based on the level of infection in their neighborhood and their risk group. A list of detailed measures for easing the restrictions was approved by the Israeli government on May 04, 2020. By April 30, the doubling period went up to several weeks with only 222 death outcomes out of 15, 946 confirmed cases. However, at the end of May, a few weeks after the government lifted most of its restrictions, the daily number of new cases started a new and prolonged increase, approaching 2, 000 around July 22.

Table 1 attempts to compare COVID-19 evolution in Israel and three European countries: Sweden, Greece, and Italy. Each of these countries has some common characteristics with Israel along with some prominent differences. In terms of population size, Sweden and Greece are similar to Israel, whereas Italy is several times bigger. On the other hand, the median age in Israel is much lower than in the other three countries, indicating a higher percentage of young population. The weather conditions in Israel are quite similar to Greece, slightly warmer than in Northern Italy, and radically different from Sweden. Also, Sweden, as a typical Scandinavian country, is normally characterised by a greater social distancing than such Mediterranean countries as Italy, Greece, and Israel.

Table 1. Comparison of COVID-19 in four countries.

Israel Sweden Greece Italy
Population (M) 8.655 10.099 10.423 60.461
Median Age 30 41 46 47
Second confirmed case 26-Feb 26-Feb 27-Feb 7-Feb
First 10 confirmed cases 1-Mar 29-Feb 5-Mar 21-Feb
First 100 confirmed cases 12-Mar 6-Mar 13-Mar 23-Feb
First death case 21-Mar 11-Mar 11-Mar 21-Feb
Mortality rate—July 31, 2020 (per 100K in population) 5.92 57.09 1.98 58.12
Confirmed cases—July 31, 2020 (per 100K in population) 819.99 763.20 42.95 409.42

Huynh [1] examined the role of the cultural dimension in practising social distancing in the beginning of the COVID-19 epidemic across 58 different countries. Social distancing data was collected from the Google COVID-19 community mobility reports covering the period from 16 February to 29 March 2020. These country–level observations were matched with cultural indices calculated in [2]. The main finding was that the country with higher ‘Uncertainty Avoidance Index (UAI)’ had less proportion in gathering at public areas during the study period.

The COVID–19 risk perception by the population may have a direct impact on the effectiveness of the public health policy. From a sample of 391 Vietnamese respondents aged from 15 to 47 years, the study [3] found that an extensive use of social media leads to a higher risk perception. In addition, people from central and southern Vietnam regions, which are popular destinations for Chinese tourists, expressed a higher risk perception of COVID-19 than those from northern Vietnam. The survey was conducted in February 2020, during the first three weeks after the official announcement of the epidemic by the Vietnamese government. The same survey also found that the high COVID–19 risk perception caused the Vietnamese citizens to wear masks in public places, even before it became an official government regulation on March 16, 2020 [4]. This could be one of the factors that mitigated the first wave of the epidemic in Vietnam. It is noteworthy that at this time (mid–September 2020), Vietnam still has an extremely low mortality rate of 0.04 per 100, 000 in population [5].

As shown in Table 1, the first multiple COVID-19 cases were detected in Israel, Sweden, and Greece around February 26, about three weeks later than in Italy. In all four countries, the number of confirmed cases has reached 100 within 1.5–2.5 weeks, with a first death case reported 2–3 weeks from the apparent start of the epidemic. However, none of the above mentioned characteristics of each country (population size, climate, age distribution, etc.) can explain such extreme differences in COVID–related mortality rates: nearly 10 times higher in Italy and Sweden than in Israel, and 3 times higher in Israel than in Greece.

According to [2], Greece has the highest Uncertainty Avoidance Index (UAI) index of 112, Sweden has one of the lowest (29), whereas Israel and Italy are ranked close to each other with UAI values of 81 and 75, respectively. The high value of UAI in Greece, possibly associated with a low level of massive gatherings [1], may provide a partial explanation for the extremely low mortality rate observed in Greece vs. the other three countries, but, apparently, UAI has nothing to do with the huge gap in mortality rates between Italy and Israel. It is also noteworthy that by the end of July 2020, Israel slightly surpassed Sweden in the number of confirmed cases per 100k in population, both countries having 2 times higher proportion of cases than Italy and 20 times higher than Greece.

The ongoing discussions of alternative “coronavirus strategies” taken by different governments brings up the following questions:

  1. What is the basic reproduction number R0 in Israel vs. other countries and how is it evolving over time?

  2. Which measures, if any, have caused the steep decrease in the daily number of new confirmed cases in Israel, which has been observed during April–May 2020, and what could be done to reverse the subsequent growth in the infection rate?

  3. What is the true Infection Rate (IR) in Israel, i.e. what is the actual fraction of infected people including those who were not tested for coronavirus during their detectable period?

  4. What are the Case Fatality Rate (CFR) and the Infection Fatality Rate (IFR), defined as the ratio of COVID-19 attributed deaths to the number of confirmed cases and the total number of infection cases, respectively? Are they changing over time?

  5. Finally, the most significant question: What is the expected evolution of the epidemic in Israel as a function of alternative intervention strategies?

The subsequent sections will focus on each one of these crucial questions. Finally, we will discuss the implications of our data analysis on the prospective decisions to be taken by the government in Israel and other countries.

Materials and methods

Data sources

For daily case count data in Israel and other countries, we rely upon the Novel Coronavirus (COVID-19) Cases Data, which is part of Humanitarian Data Exchange (HDX) platform [5]. The data is compiled since 22 January 2020 by the Johns Hopkins University Center for Systems Science and Engineering (JHU CCSE) from various sources such as the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC). The available fields include Province/State, Country/Region, Last Update, Confirmed, Suspected, Recovered, and Deaths.

The regional mortality data in Italy was downloaded from the website of the Italian Department of Civil Protection [6] on July 23, 2020. The available fields for each date and region include (translated from Italian): hospitalized with symptoms, intensive care, total hospitalized, isolated at home, total positive, total positive variation, new positive, discharged recovered, deceased, suspected cases, screening cases, total cases, swabs, cases tested.

The coronavirus geographical data in Israel was downloaded from the COVID-19 Data Repository of the Israeli Ministry of Health [7] on July 23, 2020. The available fields included: town_code, agas_code, date accumulated_tested, new_tested_on_date, accumulated_cases, new_cases_on_date, accumulated_recoveries, new_recoveries_on_date, accumulated_hospitalized, new_hospitalized_on_date, accumulated_deaths, new_deaths_on_date, town.

Modeling the infection dynamics

Following [8], we assume that the COVID-19 outbreak can be represented by SIR dynamics, which assumes that at any given point of time, each individual in the population belongs to one of the following three states: (I)nfected, (S)usceptible to infection, or (R)emoved from the transmission process. However, the original SIR model and its variations, like SEIR (susceptible–exposed–infected–recovered) [9], are continuous time models based on a set of differential equations. In contrast, we represent the COVID-19 dynamics by a discrete time model, which is more appropriate for the time series data of daily case counts. Fixing the total size of the population under a discrete time SIR model implies that the sum of the daily changes in the amount of individuals belonging to each one of the above three compartments should be equal to zero:

It+St+Ht=0 (1)

where It, St, and Ht stand for the changes in the total amount of infected, susceptible, and healed (“recovered”) people, respectively, between the days t − 1 and t. Our discrete time model for the temporal evolution of the number of infected individuals builds upon the basic reproduction number R0, which represents the average number of secondary infections an infected person will cause in a completely susceptible population before he or she is effectively removed from the population as a result of recovery, hospitalization, quarantine, etc. [8]. At the time of a pandemic, the value of R0 may be temporarily reduced by decreasing the amount of social interaction (a measure known as “social distancing”). Additional parameters used by our model include the average duration of the incubation period LI between the exposure and the onset of clinical symptoms and the generation time [LImax_TI;LI] between the primary case and the secondary case, where max_TI represents the maximum number of days from the start of the infectious period to the onset of the symptoms. We assume that symptomatic individuals are not infectious anymore as they are immediately isolated from the susceptible population and required to take a COVID-19 test. We also assume that asymptomatic people are never referred to a test and that the social behavior of infected individuals does not change during their infectious period. Given the initial size of the susceptible population N, we can define a discrete time model of infection dynamics using Eq 2.

It=R0max_TIi=t-LIt-LI+max_TI-1Ii(1-CumItN) (2)
CumIt=j=1iIj (3)
Reff=R0(1-CumItN)>1.0 (4)
CumIt*=N(1-1R0) (5)

Eq 4 shows the condition that the number of infected people continues to grow exponentially (effective reproduction number greater than 1.0). From there, using Eq 5 we can extract the herd immunity threshold, which is the minimum cumulative amount of infected individuals CumIt* that should stop an epidemic under a fixed value of R0.

Given a time series of estimated daily infections Ii, the incubation period LI, the generation time range [LImax_TI;LI], and the population size N, we can use a stochastic optimization method to find the value of R0, which should reconstruct that series with a minimal average absolute error. The error can be further reduced by splitting the time series into several segments and estimating R0 for each segment separately.

To monitor the evolution of R0 on daily basis, we can take several simplifying assumptions. First, we assume that as long as only a small proportion of a country’s population is infected, the number of susceptible individuals St remains close to the total population size N, making no difference between the basic reproduction number R0 and the effective reproduction number Reff. We also assume the generation time to be fixed to the midpoint day of the interval [LImax_TI;LI]. Applying these assumptions to Eq 2, we can approximate the expected number of new infected cases on day t as:

It=R0It-LI+max_TI/2 (6)

Eq (6) is a linear autoregressive process of order LImax_TI/2 + 1 and thus, as long as the above assumptions hold, we can use the least squares method to estimate the value of R0 from the daily counts of new infected cases. Since R0 may be affected by multiple factors, such as the level of social distancing, we can monitor its change over time by calculating the moving slope of the autoregression Eq (6) over a sliding window of n days.

To project the epidemic dynamics into the future, we just need to choose the expected value of R0, initialize the daily amounts of infected people on the last LI days before the beginning of the projection period, and start calculating the succeeding values of It recursively using Eq (2). A similar simulation paradigm was implemented in [10] to evaluate several transmission and intervention scenarios for COVID-19 in the United States over the next five years.

As long as there is no daily testing of the entire population, the exact values of It remain unknown. However, in the next sub–section, we explain how one can estimate the actual infection dynamics from the available epidemiological data.

Estimating the actual infection dynamics from available data

We assume that symptomatic individuals take a COVID-19 test on the day of the symptoms onset (the end point of the incubation period), but it takes r days on average to report a positive test result as a “confirmed case”. Given the average incubation period LI and the average reporting delay r, the time series of the daily number of new infection cases It is related to the time series of the daily number of confirmed cases Ct by Eq (7).

It=pt+LI+rCt+LI+r (7)

where pt is the reporting rate on day t, which is equal to 1 if there is a full and timely detection of all positive cases, based on daily testing of the entire population, and greater than 1 when some under–reporting takes place.

While the amount of new confirmed COVID-19 cases in various countries, regions and even cities is published on daily basis, its level of under–reporting is unknown and potentially unstable due to inconsistent testing policy, varying reporting time, and other factors and thus we cannot use it as a trustworthy indicator of the epidemic dynamics. On the other hand, the daily number of virus–related deaths Dt is expected to be much more reliable than the testing results and it should not suffer from any significant reporting delay. Assuming a fixed Infection Fatality Rate IFR, we can estimate the daily amount of infection cases on day t as a function of the amount of death outcomes on day t + LI + d, where d is the average number of days between the onset of the virus symptoms and the patient death (see Eq 8). Hence, disregarding the true value of IFR, we can explore the dynamics of the daily death rate Dt as a time–shifted substitute for the true infection rate IRt (Eq 9). Given the average reporting delay r, we can also estimate the Case Fatality Rate (CFR), which is defined in epidemiology as the proportion of people who die from a specified disease among all individuals diagnosed with the disease over a certain period of time [11]. Since the CFR numerator is restricted to deaths among people included in the denominator, we calculate it as the average ratio between the amount of death outcomes on day t + dr and the number of confirmed cases on day t (Eq 10).

It=Dt+LI+dIFR (8)
IRt=i=1tIiN (9)
CFR=Dt+d-rCt (10)

Results

The epidemic dynamics

Our analysis of COVID–19 evolution is based on the following timing parameters provided in [12, 13]:

  • Mean incubation period LI = 5.5 days

  • Minimum time from the start of the infectious period to the onset of the symptoms min_TI = 1 day

  • Maximum time from the start of the infectious period to the onset of the symptoms max_TI = 3 days

  • Mean generation period (average number of days it takes a patient to start infecting others) LImax_TI/2 = 4 days

  • Mean time between the onset of the virus symptoms and the patient death d = 11 days

  • Mean time from infection to death LI + d = 16.5 days

  • Mean time from symptoms to detection r = 4.5 days

  • Mean time from infection to detection LI + r = 10 days

  • Mean time from detection to death dr = 6.5 days

Fig 1 shows the overall evolution of the reproduction number in Israel between March 27 and July 5, 2020 along with the 14-day moving average of the daily number of death cases between March 22 and July 18, 2020. On each day, R0 was estimated as a moving slope of a linear autoregressive model over a 14-day sliding window of daily death cases Smoothed with a three-day moving average using an autoregression lag of 4 days, which is equal to the mean generation interval, and assuming that the number of deaths on day d represents the number of new infections on day d − 16. The chart also shows the main intervention measures taken by the Israeli government during the same period. Since we did not have enough mortality data to estimate the infection rate before March 27, we could not evaluate the direct effect of the school closing, which occurred around March 12, as well as business activity and movement restrictions imposed on March 19. Further measures, such as mandating masks in public (April 1) and Passover lockdown (April 7) were actually introduced when the value of R0 has already decreased below the critical level of 1.0, a trend which continued throughout the first half of May despite a fast relaxation of most restrictions enforced in March and April. As R0 went below the value of 1.0, the doubling rate (number of days required to double the number of infected people) climbed highly above the 10 days threshold, which was defined in the Government decision from May 04, 2020 as one of the criteria for rolling back the “exit strategy” steps.

Fig 1. Overall COVID–19 dynamics in Israel.

Fig 1

March 22–July 18, 2020.

After reaching an extremely low level of 0.3 around May 17 and shortly after reopening of all schools in the country (which stayed open until the end of the school year on June 20), R0 started to climb up again in a continuous trend, which included four distinct peaks on May 23 (1.1), June 12 (1.8), June 22 (1.3), and July 2 (1.4). The moving average of the daily mortality rate clearly followed the evolution of R0 with a lag of several weeks, peaking at 9.0 per day on April 19, going down to 0.6 at the end of June, and rising up to 5.0 in the second half of July. However, Fig 1 does not reveal a consistent effect of any specific measures on the actual infection rate represented by the effective reproduction number.

Fig 2 shows the local evolution of the reproduction number in four most populous Israeli cities (Jerusalem, Tel-Aviv-Yaffo, Haifa, and Rishon-Le-Zion) along with the city of Bnei-Brak, which, for various reasons, has accumulated the second largest number of confirmed COVID-19 cases in Israel despite being only no. 9 in population size. Due to relatively low daily mortality rates in each city, R0 was calculated over a 14-day sliding window of daily confirmed cases, smoothed with a five-day moving average. It is noteworthy that between the end of March and the end of May, the reproduction numbers in all five cities followed more or less the same decreasing trend. However, the months of June and July were characterised by distinct local peaks (brief but significant outbreaks), which can be easily related to fluctuations in R0 at the country level that appear in Fig 1: May 23—an outbreak in Jerusalem and Tel-Aviv, June 12—an outbreak in Haifa and Bnei-Brak, June 22—another outbreak in Jerusalem, and July 2—an outbreak in Rishon-Le-Zion.

Fig 2. Local COVID–19 dynamics in specific Israeli Cities.

Fig 2

March 30–July 17, 2020.

Fig 3 shows that, similar to Israel, the reproduction number in Greece quickly went from 1.2 down to 0.7, in parallel to domestic travel restrictions and various other lockdown measures. Despite several brief peaks in the infection rate, the overall decreasing trend continued throughout April, May, and June (when the lockdown restrictions were gradually removed), with R0 staying well below the value of 1.0 most of the time and less than one death case per day on average.

Fig 3. COVID–19 dynamics in Greece.

Fig 3

March 17–June 22, 2020.

As shown by Fig 4, the evolution of COVID-19 in Italy followed a pattern similar to Greece but on a completely different scale. The initial average value of the reproduction number in Italy was 2.5, about two times higher than in Israel and Greece, and it took it slightly more than one month to go down below 1.0, whereas the average daily number of deaths approached 800 in the beginning of April. Unlike in Israel, the lifting of lockdown restrictions in Italy was not followed by a significant increase in the value of R0, which stayed below 1.0 from mid-March until the end of July. At the same time, the daily mortality rate in Italy faced a steady descent from 700 − 800 in March to nearly 10 in July. Fig 5 indicates that COVID-19 dynamics followed a very similar trend in all six Italian regions that had the highest number of death cases.

Fig 4. COVID–19 dynamics in Italy.

Fig 4

February 14–July 09, 2020.

Fig 5. Local COVID–19 dynamics in most affected Italian regions.

Fig 5

March 11–July 21, 2020.

Fig 6 shows that the mean reproduction number in Sweden was at its peak value close to 2.0, much higher than its maximum values in Israel and Greece but lower than in Italy. Within the next two weeks it went down below 1.0, while the Swedish Government introduced various restrictions on social distancing rather than enforcing a total lockdown like in Israel, Italy, Greece, and many other countries. While it is evident that Sweden did a better job than Israel in terms of “smoothing the curve”, it experienced a relatively high mortality rate, with a peak number of about 100 cases per day at the end of April, which eventually went down below 15 in the second half of May.

Fig 6. COVID–19 dynamics in Sweden.

Fig 6

March 17–July 19, 2020.

Despite the differences in the demographic and cultural characteristics of the four countries, along with different intervention policies taken by their governments, all of them experienced quite similar dynamics of COVID-19. The initial reproduction number varied between 1.2 and 2.5 and within the following few weeks, it rapidly decreased below 1.0, disregarding the specific social distancing measures introduced during that time. Subsequently, R0 stayed below 1.0 for at least 1-2 months, without being significantly affected by various lockdown relief steps. A repeated increase in R0 observed in Israel at a later stage requires further investigation, which may have implications for other countries as well.

The true Infection Rate (IR) of COVID-19, like any other epidemic, is a non–decreasing function of time. Hopefully, it will be estimated in the near future using massive serological tests but its true past values will remain unknown forever. However, we believe, like the authors of [14], that the Test Positivity Rate (TPR) during the first few weeks of the epidemic, calculated as the fraction of positive to total tests, should be an upper bound on the true IR. Fig 7 shows the 7–day moving averages for TPR and for the daily amount of COVID-19 tests performed in Israel between March 11 and April 25. Since the mean TPR reached its peak value of 10% around March 25, when the infection rate was also at its maximum, we can conclude that the true IR in Israeli population also did not exceed 10% at that time.

Fig 7. Lab testing results in Israel.

Fig 7

March 11–April 25, 2020. Source: https://data.gov.il/dataset/covid-19.

The results of initial 1,700 serological tests performed recently in Israel [15] suggest that the true infection rate in Israel is at least 10 times higher than the number of confirmed cases. Assuming that this reporting ratio is preserved and having 56, 000 confirmed cases up to July 22, we may estimate that by that date about 6.5% of the country’s population of nearly 8.9 million have been infected with the virus. Using Eq 5 and the basic reproduction number of R0 = 1.136, which was observed at the beginning of the epidemic, we can predict that the daily number of new cases will start a steady decline after the virus prevalence will exceed 12%.

A similar antibody test conducted between April 23 and June 3 on nearly 10, 000 residents of an Italian city of Bergamo has shown about 57% of positive results [16]. Considering the total amount of 13, 600 cases confirmed in the city of 122k people around the same time, the estimated reporting ratio in Bergamo stands at about 5. Using Eq 5 and the basic reproduction number of R0 = 3.014, which was observed at the beginning of the epidemic in Lombardia Region, we can predict that the daily number of new cases in Bergamo will start a steady decline after the virus prevalence will exceed 67%, just slightly higher than 61% based on 14, 872 cases confirmed until July 22.

Figs 8, 9, 10 and 11 show the calculation of the Case Fatality Ratio (CFR) in Israel, Greece, Italy, and Sweden, respectively, as a slope of a linear regression model between the cumulative amount of confirmed cases and the cumulative number of death outcomes 7 days later. However, in all four countries, we can observe a certain decrease in the line slope, i.e., in CFR, about 2-3 months from the start of the epidemic: from 1.8% to 0.5% in Israel, from 5.9% to 1.2% in Greece, from 16% to 13% in Italy, and from 14% to 2.9% in Sweden. The high values of R-Square in all regression models indicate that most COVID-19 deaths are related to previously confirmed cases. This result supports the hypothesis that most symptomatic patients are detected by the lab tests. However, we do not have and may never have enough data to test this claim in either country. We also have no plausible explanation for the exceptionally high CFR values in Italy compared to Israel, Greece, and Sweden and to the world average of 3.6% in general. The reasons for the significant gaps between mortality rates in different countries and regions deserve a separate study as they may include differences in lab testing strategies, clinical treatment practices, outcome classification policies, coronavirus strains, etc.

Fig 8. Case fatality ratio in Israel.

Fig 8

Lag: 7 days.

Fig 9. Case fatality ratio in Greece.

Fig 9

Lag: 7 days.

Fig 10. Case fatality ratio in Italy.

Fig 10

Lag: 7 days.

Fig 11. Case fatality ratio in Sweden.

Fig 11

Lag: 7 days.

Projecting into the future

Based on the infection data estimated up to July 22, 2020 and assuming the reporting rate of p = 10 (according to the initial serology test conducted in Israel), Figs 12, 13 and 14 simulate the projected number of daily confirmed, cumulative confirmed, and cumulative death cases, respectively, for several possible values of the basic reproduction number R0. Our simulation covers the period from the end of July to the end of December 2020, when we may be close to the peak of a new flu season in Israel. These projected numbers allow us to forecast three important parameters: maximum expected number of critical patients, total amount of death outcomes, and the start of a decline in the amount of new daily infections as a result of crossing the herd immunity threshold (calculated using Eq 5). Following [13], we assume that the average hospital stay of a critical patient is equal to 20 days and that the average proportion of critical patients in Israel is about 1% of confirmed cases. Consequently, the maximum number of available critical care beds should be equal to 20% of the maximum number of daily infections. The number of critical COVID-19 patients at the end of July 2020 is very close to the above estimator based on the moving average of new daily infections detected during the last two weeks of July. The total number of death outcomes is estimated as a product of the Case Fatality Ratio observed at the end of July (0.5%) by the cumulative number of cases confirmed 7 days earlier.

Fig 12. Projected daily infection rate in Israel.

Fig 12

Up to December 31, 2020.

Fig 13. Projected cumulative infection rate in Israel.

Fig 13

Up to December 31, 2020.

Fig 14. Projected mortality rate in Israel.

Fig 14

Up to December 31, 2020.

Here is a brief discussion of each simulated scenario:

  • R0 = 1.00. This value means that the daily infection rate has started a slow decline towards less than 100 cases by the end of October and less than 10 cases by the end of December, resulting in about 300 additional deaths. This scenario will require about 360 critical care beds at its peak, slightly higher than the actual number occupied at the end of July and much lower than the maximum capacity of 1, 000 beds.

  • R0 = 1.10. This more severe scenario will increase the daily infection rate up to 1, 900 cases in the beginning of August, until, according to Eq 5, the amount of infected people in the Israeli population will reach the threshold of (1 − 1/1.1) * 100 = 9.1%, equivalent to about 79, 000 confirmed cases. Then the infection rate will start a decrease down to 100 per day by the beginning of December. At its peak, this scenario will require close to 400 critical care beds. About 700 more people are expected to die from the virus until the end of 2020.

  • R0 = 1.20. This may be the most realistic scenario, since as shown on Fig 1, similar values of the reproduction number were observed in Israel both at the beginning of the first wave, when virtually the entire population was susceptible, and during the first outbreak after the exit from the lockdown, when the population immunity was still very small. The peak is expected at the end of August, when the virus prevalence will reach (1 − 1/1.2) * 100 = 16.7%, equivalent to about 144, 000 confirmed cases. The corresponding daily infection rate of 3, 100 cases will require about 620 critical care beds, still well below the current capacity of the Israeli hospitals (1, 000 beds). Then the daily infection rate should go down to less than 100 cases by the beginning of December. Under this scenario, about 1, 100 more people are expected to die from the virus until the end of 2020.

Conclusion

The future evolution of COVID-19 in Israel and elsewhere is hardly predictable. Until a vaccine becomes available, which may happen only by the end of 2020, the governments will have to strike the tough balance between health and economic issues. As shown by Eq 4, a decrease in the basic reproduction number R0, e.g., as a result of a strict lockdown, should reduce the herd immunity threshold in terms of the total amount of infected people. However, the economic and psychological price of maintaining extreme social distancing measures until a massive vaccination program can be launched, may be too prohibitive. On the other hand, as shown by recent experience in Israel and some other countries, lifting a majority of restrictions creates a potential for multiple local outbreaks in places where R0 exceeds 1/fraction of susceptible population. In the absence of an effective vaccine, the preparedness for such “second wave” phenomena is absolutely necessary.

A further progress in understanding the current pandemic will be possible with a release of detailed clinical records of COVID-19 patients in Israel and other countries to the research community. Analyzing these records with state–of—the–art statistical and machine learning algorithms may reveal answers to many important epidemiological questions such as an accurate and early detection of high–risk patients, identification of the most infectious persons (“superspreaders”) and locations, characterization of the most common infection pathways, etc. Many thousands of human lives worldwide are at risk and, as we all know, “data saves lives”.

Acknowledgments

I thank the Israeli Ministry of Health, the Gertner Institute, and the Johns Hopkins University Center for Systems Science and Engineering for publishing the COVID-19 data used in this research. I am also grateful to Michal Feldman, Sivan Frenkel, Neil Gandal, Isidore Last, Ady Pauzner, Avraham Tabbach, Matan Yonas (Tel-Aviv University), Yoram Louzoun (Bar-Ilan University), and Lev Muchnik (Hebrew University of Jerusalem) for the fruitful discussions of some of the topics presented in this paper.

Data Availability

The data underlying the results presented in the study are available from Humanitarian Data Exchange https://data.humdata.org/event/covid-19. COVID-19 Data Repository of the Israeli Ministry of Health https://data.gov.il/dataset/covid-19.

Funding Statement

The author received no specific funding for this work.

References

Decision Letter 0

Stefan Cristian Gherghina

10 Jun 2020

PONE-D-20-13386

The First Wave of COVID-19 in Israel - Initial Analysis of Publicly Available Data

PLOS ONE

Dear Dr. Last,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The quantitative approach is too straightforward and should be seriously extended.

Please submit your revised manuscript by Jul 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Stefan Cristian Gherghina, PhD. Habil.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: While I found the article interesting and well developed, I personally believe it is too descriptive at this stage and very limited in the scope of analysis. While comparing Israel and Sweden because of similar size might sound compelling at first, more rigorous tests and comparisons are needed. The two countries have very different characteristics in terms of climate, culture, population density, rural vs. urban living, etc. - Hence, if a resubmission is intended, additional countries should be added.

Reviewer #2: This article studies the data available regarding COVID-19 infections and its fatality rate for Israel and Sweden. The aim of the study is to understand the effect of the implemented interventions and to foresee possible future scenarios.

It is an interesting study, but I have some comments on the descriptive analysis implemented.

1. The authors argue that they compare Israel and Sweden because they are countries of similar size. However, these two countries differ in many things that can affect on the evolution of the COVID19 contagion. As the author recognise, social distance is significantly different in both countries. However, there are many other substantial differences that can affect on the COVID19 dynamics such as the weather, the population density, the ability to telework, the general trust and the trust in government. It is important to discuss these substantial differences and its effect on the COVID19 dynamics.

2. The analysis would be much richer if they use data at some subnational level. It would be nice to see the analysis at the regional level. This will allow the authors also to control for some of the previous mentioned characteristics that can affect the COVI19 dynamics and that are different over the different regions in the country.

3. The linear regression that they do to estimate the correlation between confirmed cases and death should be improved. There are many characteristics that can affect in the relation of these two variables, such as the capacity of the health sector and the aging of the population. It would be very interesting if the authors implement the analysis at a regional level and departing from their initial regression, they include in a parsimonious way other control variables that can effect on the relation of these two variables. This would provide a better capacity to foresee the future scenarios depending on the regional characteristics.

4. In equation [1], the authors should replace R that refers to recovered people by another letter. It is misleading with R0

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 29;15(10):e0240393. doi: 10.1371/journal.pone.0240393.r002

Author response to Decision Letter 0


2 Aug 2020

Response to Reviewers

PONE-D-20-13386

I am extremely grateful to the anonymous reviewers for their insightful comments and suggestions.

Reviewer #1: While I found the article interesting and well developed, I personally believe it is too descriptive at this stage and very limited in the scope of analysis. While comparing Israel and Sweden because of similar size might sound compelling at first, more rigorous tests and comparisons are needed. The two countries have very different characteristics in terms of climate, culture, population density, rural vs. urban living, etc. - Hence, if a resubmission is intended, additional countries should be added.

Response: Totally agree. The analysis now includes four countries: Israel, Greece, Italy, and Sweden.

Reviewer #2: This article studies the data available regarding COVID-19 infections and its fatality rate for Israel and Sweden. The aim of the study is to understand the effect of the implemented interventions and to foresee possible future scenarios.

It is an interesting study, but I have some comments on the descriptive analysis implemented.

1. The authors argue that they compare Israel and Sweden because they are countries of similar size. However, these two countries differ in many things that can affect on the evolution of the COVID19 contagion. As the author recognise, social distance is significantly different in both countries. However, there are many other substantial differences that can affect on the COVID19 dynamics such as the weather, the population density, the ability to telework, the general trust and the trust in government. It is important to discuss these substantial differences and its effect on the COVID19 dynamics.

Response: The differences between the four analyzed countries are now discussed in the Introduction and the Results sections.

2. The analysis would be much richer if they use data at some subnational level. It would be nice to see the analysis at the regional level. This will allow the authors also to control for some of the previous mentioned characteristics that can affect the COVI19 dynamics and that are different over the different regions in the country.

Response: An excellent idea! The paper now includes regional level analysis for Israel (see Fig. 2) and Italy (see Fig. 5).

3. The linear regression that they do to estimate the correlation between confirmed cases and death should be improved. There are many characteristics that can affect in the relation of these two variables, such as the capacity of the health sector and the aging of the population. It would be very interesting if the authors implement the analysis at a regional level and departing from their initial regression, they include in a parsimonious way other control variables that can effect on the relation of these two variables. This would provide a better capacity to foresee the future scenarios depending on the regional characteristics.

Response: The correlation between confirmed cases and deaths is now explored with respect to the time dimension. Unfortunately, the effect of additional important characteristics suggested by the reviewer could not be analyzed due to the unavailability of sufficiently detailed data on the countries included in this study.

4. In equation [1], the authors should replace R that refers to recovered people by another letter. It is misleading with R0

Response: In Eq. 1, R was replaced with H, for Healed, to avoid confusion with R0.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Stefan Cristian Gherghina

7 Sep 2020

PONE-D-20-13386R1

The First Wave of COVID-19 in Israel - Initial Analysis of Publicly Available Data

PLOS ONE

Dear Dr. Last,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript requires a couple of further explanations, whereas the literature review should be extended.

Please submit your revised manuscript by Oct 22 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Stefan Cristian Gherghina, PhD. Habil.

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

Reviewer #4: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Partly

Reviewer #4: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: I read it with interest and enjoyed the clarity and brevity of your analysis. Nonetheless, I have decided not to accept immediately. While I found your analysis and literature to be interesting, the study would resonate more among our readers if it offered insights into the current literature by acknowledging these followings papers, which were focused on the Vietnam, lauded as the coronavirus fighting in the first wave. I believe that these measures as well as the study would have merits for the authors to enhance their current literature:

[a] Huynh, T. L. D. (2020). Does culture matter social distancing under the COVID-19 pandemic?. Safety Science, 104872.

[b] Huynh, T. L. D. (2020). “If You Wear a Mask, Then You Must Know How to Use It and Dispose of It Properly!”: A Survey Study in Vietnam. Review of Behavioral Economics, 7(2), 145-158.

[c] Huynh, T. L. D. (2020). The COVID-19 containment in Vietnam: What are we doing?. Journal of Global Health, 10(1).

[d] Huynh, T. L. (2020). The COVID-19 risk perception: A survey on socioeconomics and media attention. Econ. Bull, 40(1), 758-764.

[e] Huynh, T. L. D. (2020). Data for understanding the risk perception of COVID-19 from Vietnamese sample. Data in Brief, 105530.

After that, this manuscript is ready to be published.

Reviewer #4: Related to the 4th point by Reviewer 2, there are still a couple of places "R0" was written, for example p2, p12, p13. Please check and correct.

Reviewer #5: This article explores the evolution of Covid-19 in Israel compared to Greece, Italy and Sweden, and aims to understand the effect of the implemented interventions and to predict possible future scenarios. Even though it is mostly at descriptive level, concerning that every single piece of analysis adds to the information set of humanity, it might be valuable to publish it, once the necessary implementations are made.

It seems that the author successfully implemented most of the recommendations of the referees. He added two more countries, Greece and Italy, and two subnational analysis, one for Israel and one for Italy. Additionally, the graphs and the regression analyses are clearer and that`s why make more sense compared to the initial submission. Thus, I think the paper has improved a lot.

I would recommend couple of minor additions:

1. The “Current mortality rate” needs an explanation of what that current date is. Plus a “current number of confirmed cases per 100K” would be added to Table 1 to give a clearer picture.

2. The y-axis of Figure 2 is not stated. The author should add a title to that axis.

3. I do not think the author needs to spend 3-4 sentences per figure to explain everything in the Figures 3-4-5. They are already very clear. He can safely remove some. This will shorten the paper a little.

Once these minor additions are added, I think the paper will add to the literature and can be published.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

Reviewer #5: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 29;15(10):e0240393. doi: 10.1371/journal.pone.0240393.r004

Author response to Decision Letter 1


23 Sep 2020

Response to Reviewers

PONE-D-20-13386R1

I am again extremely grateful to the anonymous reviewers for their additional comments and suggestions.

Reviewer #3: I read it with interest and enjoyed the clarity and brevity of your analysis. Nonetheless, I have decided not to accept immediately. While I found your analysis and literature to be interesting, the study would resonate more among our readers if it offered insights into the current literature by acknowledging these followings papers, which were focused on the Vietnam, lauded as the coronavirus fighting in the first wave. I believe that these measures as well as the study would have merits for the authors to enhance their current literature:

[a] Huynh, T. L. D. (2020). Does culture matter social distancing under the COVID-19 pandemic?. Safety Science, 104872.

[b] Huynh, T. L. D. (2020). “If You Wear a Mask, Then You Must Know How to Use It and Dispose of It Properly!”: A Survey Study in Vietnam. Review of Behavioral Economics, 7(2), 145-158.

[c] Huynh, T. L. D. (2020). The COVID-19 containment in Vietnam: What are we doing?. Journal of Global Health, 10(1).

[d] Huynh, T. L. (2020). The COVID-19 risk perception: A survey on socioeconomics and media attention. Econ. Bull, 40(1), 758-764.

[e] Huynh, T. L. D. (2020). Data for understanding the risk perception of COVID-19 from Vietnamese sample. Data in Brief, 105530.

After that, this manuscript is ready to be published.

Response: I found the above references very useful and extended the literature survey in the Introduction section accordingly.

Reviewer #4: Related to the 4th point by Reviewer 2, there are still a couple of places "R0" was written, for example p2, p12, p13. Please check and correct.

Response: checked and corrected as necessary.

Reviewer #5: This article explores the evolution of Covid-19 in Israel compared to Greece, Italy and Sweden, and aims to understand the effect of the implemented interventions and to predict possible future scenarios. Even though it is mostly at descriptive level, concerning that every single piece of analysis adds to the information set of humanity, it might be valuable to publish it, once the necessary implementations are made.

It seems that the author successfully implemented most of the recommendations of the referees. He added two more countries, Greece and Italy, and two subnational analysis, one for Israel and one for Italy. Additionally, the graphs and the regression analyses are clearer and that`s why make more sense compared to the initial submission. Thus, I think the paper has improved a lot.

I would recommend couple of minor additions:

1. The “Current mortality rate” needs an explanation of what that current date is. Plus a “current number of confirmed cases per 100K” would be added to Table 1 to give a clearer picture.

Response: The word “current” was replaced with specific dates, where applicable (including Table 1). The number of confirmed cases was added to Table 1 as well.

2. The y-axis of Figure 2 is not stated. The author should add a title to that axis.

Response: The y-axis title added.

3. I do not think the author needs to spend 3-4 sentences per figure to explain everything in the Figures 3-4-5. They are already very clear. He can safely remove some. This will shorten the paper a little.

Response: Several sentences removed.

Once these minor additions are added, I think the paper will add to the literature and can be published

Attachment

Submitted filename: Response to Reviewers2.docx

Decision Letter 2

Stefan Cristian Gherghina

28 Sep 2020

The First Wave of COVID-19 in Israel - Initial Analysis of Publicly Available Data

PONE-D-20-13386R2

Dear Dr. Last,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Stefan Cristian Gherghina, PhD. Habil.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: This revised version incorporated all my comments. Therefore, I am quite optimistic about the publishing opportunity from this manuscript.

Reviewer #5: This article aims to address the effect of the implemented interventions across various countries to predict possible future scenarios. The authors successfully implemented all of my recommendations and most of the others referees` too.

Well-done. Congratulations

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Toan Luu Duc Huynh

Reviewer #5: Yes: Orhan Erdem

Acceptance letter

Stefan Cristian Gherghina

5 Oct 2020

PONE-D-20-13386R2

The First Wave of COVID-19 in Israel – Initial Analysis of Publicly Available Data

Dear Dr. Last:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Stefan Cristian Gherghina

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers2.docx

    Data Availability Statement

    The data underlying the results presented in the study are available from Humanitarian Data Exchange https://data.humdata.org/event/covid-19. COVID-19 Data Repository of the Israeli Ministry of Health https://data.gov.il/dataset/covid-19.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES